Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In May last year (i.e., May 2010), the Prostate Cancer Foundation announced a partnership with Johns Hopkins and Cedars-Sinai to set up a national, proactive prostate cancer surveillance initiative. We reported this announcement … and then we heard no more.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, National Proactive Surveillance Network, registry, trial | Leave a Comment »
Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: mCRPC, Phase III, Prostvac, trial | 4 Comments »
Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC):
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, mCRPC, pain, Phase III, trial | Leave a Comment »
The SELECT study has previously shown that treatment with selenium did not prevent prostate cancer in your average “guy in the street.” However, what about men with a prior diagnosis of high-grade prostatic intraepithelial neoplasia (HG-PIN)?
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: HG-PIN, prostatic intraepithelial neoplasia, selenium, trial | Leave a Comment »
In 1989 the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) started randomizing men with a clinically initiated diagnosis of localized prostate cancer to either watchful waiting or open radical prostatectomy as their primary treatment. A new paper has now addressed the long-term quality of life (QoL) of men in this study.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse effects, outcome, quality of life, radical prostatectomy, Scandinavian, SPCG-4, trial, watchful waiting | Leave a Comment »
There has been considerable interest in the ability of so-called “heat shock protein” (HSP) inhibitors to be used alone or in combination with other agents to delay the progression of a number of types of cancer, and of advanced forms of prostate cancer in particular.
Filed under: Drugs in development | Tagged: heat shock protein, HSP, inhibitor, IPI-504, OGX-427, outcome, trial | 2 Comments »
A new study just published in The Lancet has reported that — among men who have urinary incontinence 6 weeks after a radical prostatectomy (RP) — formal one-on-one training of patients by expert therapists does not in fact reduce the rate of continence at 12 months compared to patients in a control group.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: continence, exercises, incontinence, Kegel, outcome, radical prostatectomy, randomized, training, trial | 4 Comments »
According to a media release from Regeneron Pharmaceuticals, the company plans to continue the randomized, multi-center, Phase III VENICE clinical trial, designed to evaluate the efficacy and safety of aflibercept (ZALTRAP™) in combination with docetaxel in the first-line treatment of patients with metastatic, hormone-refractory prostate cancer.
Filed under: Drugs in development | Tagged: aflibercept, hormone refractory, Regeneron, trial | 8 Comments »
Out of the 600+ presentations at the IMPaCT meeting in Orlando last week, your correspondent somehow managed to overlook an interesting poster that offers new evidence in support of the potential benefit of statin therapy in the prevention and management of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Prevention, progression, statin, trial | 2 Comments »
One of the problems with prostate cancer is that it can take many years for the disease to develop from a very small group of cells in a man’s prostate into a disorder that has actual clinical significance.
Filed under: Diagnosis, Risk | Tagged: clinically significant, early stage, ethics, Malmo, prognosis, trial | Leave a Comment »
The idea that the soy isoflavone known as genistein might prove to be a non-toxic therapeutic agent for the prevention and/or treatment of prostate cancer has now been around for so long that the idea appears to have become a perceived truth in some quarters.
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: genistein, isoflavone, outcome, soy, trial | Leave a Comment »
According to a media release issued earlier today, Medivation and Astellas Pharma have enrolled the first patient into a new Phase III clinical trial of MDV3100.
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, MDV3100, Phase III, trial | Leave a Comment »
According to a media release from a division of Johnson & Johnson earlier today, an independent data monitoring committee has recommended that patients in the placebo arm of a Phase III trial of abiraterone acetate be offered treatment with abiraterone following unblinding of study data.
Filed under: Drugs in development | Tagged: abiraterone, early access, trial | 8 Comments »
Many patients have sought out acupuncture as a method to gain relief from hot flashes associated with androgen deprivation therapy (ADT). However, data from prospective clinical trials is at best limited.
Filed under: Living with Prostate Cancer, Management | Tagged: acupuncture, ADT, androgen deprivation, hot flashes, trial | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site